

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. 10/749,118 Art Unit: 1645
Applicant: Boyd Examiner: Not Yet Assigned
Date Filed: December 30, 2003 Conf. No. Not Yet Assigned
Docket Nos. NOR-012CP2 and 286336.151US1 Cust. No. 23483
Title: Normalization of Defective T Cell Responsiveness Through Manipulation of Thymic Regeneration

CERTIFICATION UNDER 37 C.F.R. § 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" Service under 37 C.F.R. § 1.10 on the date indicated below and is addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EV 507045291 US
Express Mail No.

1/21/05
Date of Deposit

Brenda L. Robles
Brenda L. Robles

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant and its legal representatives hereby make of record on the attached PTO Form-1449 the following publications. This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b)(3) before the mailing date of a first Office Action on the merits, therefore no fee is due. I hereby state under 37 C.F.R. § 1.97 (e)(1) that each item of information contained in this Information Disclosure Statement was cited in a communication (copy enclosed) from a foreign patent office on a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

A copy of the cited U.S. patent reference is not enclosed. Copies of all other publications are enclosed. If the Examiner requires a copy of the cited U.S. patent reference, he/she is invited to contact the undersigned agent for the Applicant.

It is respectfully requested that the information above be expressly considered during the prosecution of this application and that the publications be made of record therein and appear among the "References Cited" on any patent to issue therefrom. *In this regard, it is requested that the Examiner initial and return a copy of the enclosed Form PTO-1449 with the next Patent Office Communication.*

This submission does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art. If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

No fees are believed to be due in connection with this matter; however, please charge any fees that might be due to Deposit Account No. 08-0219.

Respectfully submitted,

Date: January 20, 2005

Ann-Louise Kerner
Ann-Louise Kerner, Ph.D.
Reg. No. 33,523
Attorney/Agent for Applicant

WILMER CUTLER PICKERING HALE AND DORR LLP
60 State Street
Boston, MA 02109
(617) 526-6000
(617) 526-5000 (Facsimile)

Sub. For, PTO-1449 INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)				Docket Numbers NOR-012CP2 and 286336.151US1	Application Number 10/749,118
				Applicant Boyd	
Sheet	1	OF	1	Filing Date December 30, 2003	Group Art Unit 1645

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,103,694	Aug 15, 2000	Mardiney, III et al.	514	12	Apr 10, 1998

Foreign Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)		
A265	Ghalie et al., "Prevention of Hypermenorrhea With Leuprolide in Premenopausal Women Undergoing Bone Marrow Transplantation," American Journal of Hematology, 1993, Vol. 42, pp 350-353	
A266	Kojima et al., "Immunosuppressive Therapy Using Antithymocyte Globulin, Cyclosporine, and Danazol With or Without Human Granulocyte Colony-Stimulating Factor in Children With Acquired Aplastic Anemia," Blood, September 15, 2000, Vol. 96, No. 6, pp 2049-2054	
A267	Masera et al., "Is Orchiectomy Indicated Before BMT in Childhood ALL?" Bone Marrow Transplant, 1991, Vol. 8, No. S1, pp 33-35	
A268	Vogelsang et al., "Thalidomide Induction of Bone Marrow Transplantation Tolerance," Transplantation Proceedings, 1987, Vol. XIX, No. 1, pp 2658-2661	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	